

GENTA INC DE/  
Form 8-K  
July 27, 2006

---

---

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

---

FORM 8-K

CURRENT REPORT

PURSUANT TO SECTION 13 OR 15(d) OF THE  
SECURITIES EXCHANGE ACT OF 1934

Date of report (Date of earliest event reported): July 27, 2006

GENTA INCORPORATED  
(Exact Name of Registrant as Specified in Charter)

|   |                                       |   |
|---|---------------------------------------|---|
| Delaware<br>(State or Other Jurisdiction<br>of Incorporation) | 000-19635<br>(Commission File Number) | 33-0326866<br>(I.R.S. Employer<br>Identification No.) |
|---|---------------------------------------|---|

|   |                     |
|---|---------------------|
| Two Connell Drive, Berkeley Heights, NJ<br>(Address of Principal Executive Offices) | 07922<br>(Zip Code) |
| (908) 286-9800<br>(Registrant's telephone number, including area code)              |                     |

(Former Name or Former Address, if Changed Since Last Report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)  
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)  
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17  
CFR 240.14d-2(b))  
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17  
CFR 240.13e-4(c))

---

---

Item 8.01 Other Events.

On July 27, 2006, Genta Incorporated, a Delaware corporation (the “Company”), issued a press release announcing that the Company has been notified by the Food and Drug Administration (FDA) that the Oncology Drug Advisory Committee (ODAC) will review the New Drug Application (NDA) for Genasense® (oblimersen sodium) Injection plus chemotherapy for the treatment of patients with relapsed or refractory chronic lymphocytic leukemia (CLL) on September 6, 2006.

A copy of the press release is filed as Exhibit 99.1 to this report and incorporated herein by reference.

---

Item 9.01 Financial Statements and Exhibits.

(d) Exhibits.

| Exhibit No. | Description                                       |
|-------------|---|
| 99 .1       | Press Release of the Company dated July 27, 2006. |

---

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

GENTA INCORPORATED  
By: /s/ Richard J. Moran  
Richard J. Moran  
Senior Vice President, Chief Financial  
Officer and Corporate Secretary

Dated: July 27, 2006